Drug Profile


Alternative Names: (R,R)-eformoterol; (R,R)-formoterol; Arformoterol tartrate; Arformoterol tartrate inhalation; Brovana; Eformoterol - Sunovion; Formoterol - Sunovion; R,R-eformoterol; R,R-formoterol

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Sepracor
  • Developer Sunovion Pharmaceuticals
  • Class Antiasthmatics; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Asthma

Most Recent Events

  • 08 Mar 2016 Biomarkers information updated
  • 01 Nov 2014 Discontinued - Phase-II for Asthma (In children) in USA (Inhalation)
  • 08 Jul 2014 Final efficacy and adverse events data from a phase III trial in Chronic obstructive pulmonary disease released by Sunovion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top